Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.60 |
| ▸ | TACR2 | P21452 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | ERN1 | O75460 | 1/20 | 0.50 |
| ▸ | RORC | P51449 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.49 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.49 |
| ▸ | FDPS | P14324 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30902399 | 1.00 | ALDH1A1 (0.60) | ALDH1A1TACR2L3MBTL1HPGDTDP1 | |
| Benzene SCHEMBL27642249 | 0.97 | TACR2 (0.57) | ALDH1A1TACR2L3MBTL1HPGDTDP1 | |
| SCHEMBL566342 | 0.86 | CSNK2A1 (0.55) | ALDH1A1TACR2L3MBTL1HPGDTDP1 | |
| SCHEMBL1121447 | 0.86 | ALDH1A1 (0.65) | ALDH1A1TACR2L3MBTL1HPGDTDP1 | |
| SCHEMBL5702962 | 0.85 | ALDH1A1 (0.60) | ALDH1A1TACR2L3MBTL1HPGDTDP1 | |
| SCHEMBL566481 | 0.85 | FDPS (0.53) | ALDH1A1TACR2L3MBTL1HPGDTDP1 | |
| SCHEMBL566676 | 0.83 | FDPS (0.51) | ALDH1A1TACR2L3MBTL1HPGDTDP1 | |
| SCHEMBL493684 | 0.83 | ALDH1A1 (0.73) | ALDH1A1TACR2L3MBTL1HPGDTDP1 | |
| SCHEMBL30159697 | 0.83 | ALDH1A1 (0.73) | ALDH1A1TACR2L3MBTL1HPGDTDP1 | |
| SCHEMBL31471675 | 0.83 | ALDH1A1 (0.50) | ALDH1A1TACR2L3MBTL1HPGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4727079-A | Brain-specific dopaminergic activity involving dihydropyridine carboxamides, dihydroquinoline and isoquinoline carboxamides | UNIVERSITY OF FLORIDA (US) | 1988-02-23 | — | — | US | claimed |
| EP-4619097-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF | Samsara Therapeutics Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| WO-2025106477-A1 | NOVEL AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF | Samsara Therapeutics Inc. (US) | 2025-05-22 | — | — | WO | disclosed |
| WO-2024107434-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF | Samsara Therapeutics Inc. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024105007-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF | Samsara Therapeutics Inc. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024107434-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF | Samsara Therapeutics Inc. (US) | 2024-05-23 | — | — | WO | disclosed |
| CN-116251081-A | 3-arylindenone compounds and pharmaceutical uses thereof | 复旦大学 | 2023-06-13 | — | — | CN | disclosed |
| US-20230158025-A1 | GALACTOKINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH | 2023-05-25 | — | — | US | disclosed |
| WO-2021216812-A1 | GALACTOKINASE INHIBITORS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2021-10-28 | — | — | WO | disclosed |
| EP-3219717-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (R)-N-METHYLNALTREXONE | Progenics Pharmaceuticals, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| EP-0036426-A1 | NOVEL PROCESS AND INTERMEDIATES USEFUL IN THE PREPARATION OF SYMPATHOMIMETIC AMINES. | INTERX RESEARCH CORP (US) | 1981-09-30 | — | — | EP | disclosed |
| US-4285947-A | DIURETICS, HYPOTENSIVES | INTERX RESEARCH CORPORATION (US) | 1981-08-25 | — | — | US | disclosed |
| EP-0032725-A1 | Novel aldehyde adducts of triamterene and a pharmaceutical composition containing the same | MERCK & CO. INC. (US) | 1981-07-29 | — | — | EP | disclosed |
| US-4275219-A | Novel process and intermediates useful in the preparation of sympathomimetic amines | INTERX RESEARCH CORPORATION (US) | 1981-06-23 | — | — | US | disclosed |
| WO-1981000849-A1 | NOVEL PROCESS AND INTERMEDIATES USEFUL IN THE PREPARATION OF SYMPATHOMIMETIC AMINES | INTERX RESEARCH CORP (US) | 1981-04-02 | — | — | WO | disclosed |
| US-RE30241-E | BRONCHODILATION, ADRENERGIC STIMULANTS | STERLING DRUG INC. (US) | 1980-03-25 | — | — | US | disclosed |
| US-4145441-A | SYMPATHOMIMETIC AMINES EXHIBITING ANTI-HEMORRHOIDAL ACTIVITY | INTERX RESEARCH CORPORATION (US) | 1979-03-20 | — | — | US | disclosed |
| US-4138581-A | BRONCHODILATOR AGENTS, ADRENERGIC STIMULANTS | STERLING DRUGS INC. (US) | 1979-02-06 | — | — | US | disclosed |
| US-4094983-A | \"KETO\" SYMPATHOMIMETIC AMINES | INTERX RESEARCH CORPORATION (US) | 1978-06-13 | — | — | US | disclosed |
| US-4035405-A | Novel synthesis for preparing the hydrochloride salt of selected catecholamine derivatives | INTERX RESEARCH CORPORATION (US) | 1977-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158025-A1 | GALACTOKINASE INHIBITORS | GALK1, GCK, GCKR | ALDH1A1 3139/4885TACR2 2935/4885L3MBTL1 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.